NASDAQ:HSKA
Delisted
Heska Corporation Stock News
$119.99
+0 (+0%)
At Close: Sep 11, 2023
Heska (HSKA) Q1 Earnings and Revenues Lag Estimates
10:40am, Friday, 05'th May 2023
Heska (HSKA) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.27 per share a year ago.
Why Heska Stock Is On Fire Today
11:31am, Monday, 03'rd Apr 2023
Heska and privately-held Mars have agreed to a buyout offer of $120 per share. This deal underscores the high-growth potential of pet products companies.
Heska Corporation (HSKA) Q4 2022 Earnings Call Transcript
10:29pm, Tuesday, 28'th Feb 2023
Heska Corporation (NASDAQ:HSKA ) Q4 2022 Earnings Conference Call February 28, 2023 11:00 AM ET Company Participants Jon Aagaard - Investor Relations Kevin Wilson - Chief Executive Officer and Preside
Heska (HSKA) Q4 Earnings and Revenues Surpass Estimates
12:48pm, Tuesday, 28'th Feb 2023
Heska (HSKA) delivered earnings and revenue surprises of 44.74% and 3.72%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Heska (HSKA) Moves to Buy: Rationale Behind the Upgrade
01:33pm, Monday, 13'th Feb 2023
Heska (HSKA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Heska Corp's CEO Loads Up on Shares After 70% Nosedive
06:30pm, Thursday, 12'th Jan 2023
One of the more unexpected market bubbles that developed from Covid-related easy money policies was the “pet stock” bubble. As people were stuck at home more often, they were more likely to adopt
Heska (HSKA) Moves 9.0% Higher: Will This Strength Last?
09:47am, Wednesday, 11'th Jan 2023
Heska (HSKA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Heska Corporation (HSKA) Q3 2022 Earnings Call Transcript
03:37pm, Saturday, 12'th Nov 2022
Heska Corporation (NASDAQ:HSKA ) Q3 2022 Results Conference Call November 8, 2022 11:00 AM ET Company Participants Jon Aagaard - Director, IR Kevin Wilson - President and CEO Catherine Grassman - EVP
Heska Corp (HSKA) CEO Kevin Wilson on Q2 2022 Results - Earnings Call Transcript
05:10pm, Monday, 08'th Aug 2022
Heska Corp (NASDAQ:HSKA ) Q2 2022 Earnings Conference Call August 8, 2022 11:00 AM ET Company Participants Jon Aagaard - Director, IR Kevin Wilson - CEO, President Catherine Grassman - EVP & CFO Confe
5 Toxic Stocks That May Prove Hazardous for Your Portfolio
09:02am, Monday, 08'th Aug 2022
Toxic companies are characterized by huge debt pile and are vulnerable to external shocks. Accurately identifying such stocks and getting rid of them at the right time can protect your portfolio.
Analyst Ratings for Heska
01:16pm, Tuesday, 10'th May 2022 Benzinga
Over the past 3 months, 4 analysts have published their opinion on Heska (NASDAQ:HSKA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's
Heska Corp (HSKA) CEO Kevin Wilson on Q1 2022 Results - Earnings Call Transcript
01:56pm, Monday, 09'th May 2022
Heska Corp (NASDAQ:HSKA ) Q1 2022 Earnings Conference Call May 9, 2022 11:00 AM ET Company Participants Jon Aagaard - Director, IR Kevin Wilson - CEO, President & Director Catherine Grassman - EVP & C
Heska (HSKA) Misses Q1 Earnings and Revenue Estimates
01:35pm, Monday, 09'th May 2022 Zacks Investment Research
Heska (HSKA) delivered earnings and revenue surprises of -34.15% and 3.44%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Heska (HSKA) Misses Q1 Earnings and Revenue Estimates
11:18am, Monday, 09'th May 2022
Heska (HSKA) delivered earnings and revenue surprises of -34.15% and 3.44%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates
01:25pm, Thursday, 05'th May 2022 Zacks Investment Research
Mirum Pharmaceuticals, Inc. (MIRM) delivered earnings and revenue surprises of 15.83% and 48.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the s